Hospital Arnau De Vilanova De Valencia — Clinical Trial Site

88 Registered trials

28 Currently recruiting

Organisation

Hospital Arnau De Vilanova De Valencia

Location

Valencia, Spain

Identifier

ORG-100041230

Address

Calle De San Clemente 12, 46015, Spain

Departments

-
#2356: Servicio de dermatología
1407:Dermatología
6508: Dermatología
7001: Oncología Médica
7005: Hematología
9758; Dermatología
Allergology
Cardiology
Departamento de Oncología
Dermatology
ESP002: Oncología Médica
Gastroenterology and Hepatology
Hematología
Hematology
Intensive Care Unit
Medical Oncology
Medicine
NEUMOLOGÍA
Neumology
Oncología Médica
Oncology
Oncology department
Ophthalmology
Pediatria
Pneumology
Pulmonology
Servicio de Cardiologia
Servicio de Dermatología
Servicio de Hematología
Servicio de Hematología y Hemoterapia
Servicio de Medicina Interna
Servicio de Neumología
Servicio de Oncología
Thoracic Oncology
Unidad de Ensayos Clínicos

Clinical trials at this site (88)

Search interface

A Study of Nivolumab + Relatlimab Fixed-dose Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy in Participants with Non-s… Recruiting

2024-513682-40-01 Non-squamous (NSQ), Stage IV or Recurrent Non-small Cel 5 2025-07-04
Study of Adagrasib plus Pembrolizumab plus Chemotherapy vs. Placebo plus Pembrolizumab plus Chemotherapy in Participants with Previously Unt… Recruiting

2024-515698-85-00 Locally Advanced or Metastatic Non-small Cell Lung Canc 5 2025-06-12
Non-Invasive Ventilation versus High Flow Oxygenotherapy in Patients at High Risk of Extubation Failure Recruiting

2024-514640-81-00 Weaning of Mechanical ventilation 6 2025-04-23
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Compensate… Recruiting

2024-512895-36-00 Metabolic Dysfunction-Associated Steatohepatitis (MASH) 5 2024-11-25
Phase II Study to Assess the Efficacy of Niraparib Rechallenge after Surgery in Ovarian Cancer Patients with Oligometastatic Progression (Th… Recruiting

2023-508258-24-00 Ovarian cancer (OC) with oligometastatic progression (O 4 2024-09-12
Trastuzumab Deruxtecan (T-DXd) for Subjects with Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC0 Breast Cancer… Recruiting

2023-505616-38-00 Unresectable and/or Metastatic HER2-low or HER2 Immunoh 4 2024-09-04
A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Lisaftoclax (APG-2575) in Previously Treated Patients with Chro… Recruiting

2023-508005-24-00 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 5 2024-08-01
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting

2023-504031-41-00 ER+/HER2- Early Breast Cancer 5 2024-03-25
A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF)… Recruiting

2023-504323-25-01 breast cancer 5 2024-03-19
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Non-Cirrho… Recruiting

2023-505141-48-00 Fibrosis 5 2024-03-07
A study to Evaluate Efficacy and Safety of Giredestrant Compared with Fulvestrant (plus a CDK4/6 inhibitor), in Participants with ER+ HER2-N… Recruiting

2022-502980-39-00 Estrogen receptor (ER)-positive, HER2-negative advanced 5 2024-01-25
A Phase 1b/2, Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic B… Recruiting

2022-503114-23-00 Breast Cancer 3 2023-12-19
LONG-TERM FOLLOW-UP STUDY OF EARLY STAGE BREAST CANCER PATIENTS INCLUDED IN GEICAM STUDIES Recruiting

2022-502706-33-00 Patients with invasive breast cancer in early stages 6 2018-01-10
A dose finding study with an anti-TSLP antibody (GSK5784283) in adults aged 18 to 75 years of age with uncontrolled asthma. Ended

2024-518321-15-00 Asthma 4 2025-05-30
"Neoadjuvant phase II study of pembrolizumab and carboplatin plus paclitaxel for stage I triple-negative breast cancer (The TELESCOPE study)… Ended

2024-513511-27-00 HR-negative/HER2-negative resectable stage I TNBC. 4 2025-05-29
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Letrozole in People Over 18 Years of Age With HR-Positive, … Ended

2024-512925-95-00 Advanced/Metastatic Breast Cancer 5 2025-05-16
A Multicenter, Open-Label, Single-Arm, Phase II Trial Exploring the Maintenance of Trastuzumab and Pertuzumab Following Trastuzumab Deruxtec… Ended

2023-507306-13-00 HER2-positive unresectable locally recurrent or metasta 4 2025-04-13
A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy,… Ended

2023-505739-12-01 Chronic Inducible Urticaria (CINDU) 5 2024-09-30
A Study of Lepodisiran (LY3819469) in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) Ended

2023-509190-23-00 Atherosclerotic Cardiovascular Disease Elevated lp(a) 5 2024-09-03
Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis Ended

2023-508235-31-00 Atopic Dermatitis 5 2024-06-17
Phase II Study of Trastuzumab-Deruxtecan (T-DXd; DS-8201a) in HER2-Low Breast Cancer Patients Presenting with Newly Diagnosed or Progressing… Ended

2023-506702-39-00 HER2-low breast cancer presenting with newly diagnosed 4 2024-06-05
REIMAGINE – Real-world EvaluatIon of Mepolizumab in severe Asthma achievinG on treatment clinIcal remissioN, a prospEctive study. Ended

2023-509026-21-00 severe asthma 6 2024-06-03
52 weeks double-blind, double-dummy, randomized placebo-controlled trial to evaluate safety, efficacy and tolerability of remibrutinib in co… Ended

2022-502161-19-00 Chronic Spontaneous Urticaria 5 2024-03-12
A study of LOXO-783 in Patients with PIK3CA H1047R-Mutant Advanced Breast Cancer and Other Solid Tumors. Ended

2023-509568-81-00 Advanced Breast Cancer and Other Solid Tumors 1 2023-07-27